Intensity modulated radiation therapy (IMRT) following prostatectomy: more favorable acute genitourinary toxicity profile compared to primary IMRT for prostate cancer.

PURPOSE To report our initial experience on postprostatectomy IMRT (PPI), addressing acute genitourinary (GU) toxicity in comparison to primary IMRT (PI) for prostate cancer. METHODS AND MATERIALS From April 1998 to December 1999, 40 postprostatectomy patients were treated with intensity modulated radiation therapy (IMRT) to a median prescribed dose of 64 Gy (mean dose of 69 Gy). The Radiation Therapy Oncology Group (RTOG) scoring system was used to assess acute GU toxicity. Target volume and maximum and mean doses were evaluated. The mean doses to the bladder and irradiated bladder volume receiving >65 Gy were assessed. These were compared to those of 125 patients treated with PI to a prescribed dose of 70 Gy (mean dose of 76 Gy). RESULTS The acute GU toxicity profile is more favorable in the PPI group with 82.5% of Grade 0-1 and 17.5% of Grade 2 toxicity compared to 59.2% and 40.8%, respectively, in the PI group (p < 0.001). There was no Grade 3 or higher toxicity in either group. The target volume was larger in the PPI group, while the maximum and mean doses to the target were higher in the PI group. The mean dose delivered to the bladder was higher in the PPI group. The irradiated bladder volume receiving >65 Gy was significantly larger in the PI group (p < 0.001). CONCLUSIONS PPI can be delivered with acceptable ute GU toxicity. The larger PPI target volume may be related to the difficulty in delineating prostatic fossa. Despite a larger target volume and a higher mean dose to the bladder, PPI produced a more favorable acute GU toxicity profile. This may be related to a combination of lower mean and maximum doses and smaller bladder volumes receiving >65 Gy in the PPI group, as well as urethral rather than bladder irradiation. The findings have implications in the evaluation of IMRT treatment plan for prostate cancer, whereby the irradiated bladder volumes above 65 Gy may be more meaningful than the mean dose to the bladder. Longer term toxicity results are awaited.

[1]  A. W. Kemp,et al.  Medical Uses of Statistics. , 1994 .

[2]  G J Kutcher,et al.  Three-dimensional conformal radiotherapy and dose escalation: where do we stand? , 1998, Seminars in radiation oncology.

[3]  E. B. Butler,et al.  Does the "peacock" have anything to do with radiotherapy? , 1994, International journal of radiation oncology, biology, physics.

[4]  J. Purdy Intensity-modulated radiation therapy. , 1996, International journal of radiation oncology, biology, physics.

[5]  M van Herk,et al.  Variation in volumes, dose-volume histograms, and estimated normal tissue complication probabilities of rectum and bladder during conformal radiotherapy of T3 prostate cancer. , 1995, International journal of radiation oncology, biology, physics.

[6]  Chantal Ginestet,et al.  Acute toxicity in pelvic radiotherapy; a randomised trial of conformal versus conventional treatment , 1997 .

[7]  P. Scardino,et al.  Intensity-modulated radiation therapy (IMRT) for localized prostate cancer: A comparison of peacock conformal treatment volumes and pathologic radical prostatectomy specimens , 1998 .

[8]  M. Zelefsky,et al.  Tolerance and early outcome results of postprostatectomy three-dimensional conformal radiotherapy. , 1997, International journal of radiation oncology, biology, physics.

[9]  P. Levendag,et al.  Acute morbidity reduction using 3DCRT for prostate carcinoma: a randomized study. , 1999, International journal of radiation oncology, biology, physics.

[10]  G Starkschall,et al.  Conventional vs. conformal radiotherapy for prostate cancer: preliminary results of dosimetry and acute toxicity. , 1996, International journal of radiation oncology, biology, physics.

[11]  K. Godfrey Comparing the Means of Several Groups , 1985, Medical Uses of Statistics.

[12]  D. Hussey American Society for Therapeutic Radiology and Oncology , 2001 .

[13]  E. B. Butler,et al.  Intensity modulated radiation therapy (IMRT): a new promising technology in radiation oncology. , 1999, The oncologist.

[14]  P. Schellhammer,et al.  Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  T. Pajak,et al.  Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) , 1995, International journal of radiation oncology, biology, physics.

[16]  B. Corn,et al.  Does androgen suppression enhance the efficacy of postoperative irradiation? A secondary analysis of RTOG 85-31. Radiation Therapy Oncology Group. , 1999, Urology.

[17]  W. Grant,et al.  2271 Intensity modulated radiotherapy (IMRT) for prostate cancer: Rectal mucosal sparing by dosimetric effect of a rectal balloon , 1999 .

[18]  C. Yu,et al.  A systematic evaluation of air cavity dose perturbation in megavoltage x-ray beams. , 2000, Medical physics.